Ivabradina Sandoz (Ivabradine Oxalate)

Ivabradina Sandoz acts on the cardiac If current to manage conditions where heart‑rate reduction is therapeutic.

• Chronic stable angina: improves exercise tolerance and decreases frequency of angina attacks.
• Heart failure with reduced ejection fraction: lowers resting heart rate and may enhance symptom control.
• Elevated heart rate despite optimal therapy: provides additional rate control when beta‑blockers are insufficient or not tolerated.

• Ivabradine selectively inhibits the funny (If) current in sinoatrial node cells, which slows depolarisation of pacemaker cells. By reducing the slope of phase 4 depolarisation, the drug decreases spontaneous heart‑rate without affecting myocardial contractility, ventricular repolarisation, or blood pressure, thereby providing rate control in angina and heart‑failure patients.

Adverse reactions may occur with Ivabradina Sandoz and are reported in clinical use.

Common Side Effects

• Visual disturbances (phosphenes): transient luminous phenomena.
• Bradycardia: heart rate below prescribed limits.
• Headache: mild to moderate intensity.
• Dizziness or vertigo: especially on standing.
• Fatigue: general feeling of tiredness.
• Nausea: occasional gastrointestinal upset.

Serious or Rare Side Effects

• Symptomatic bradycardia requiring medical attention.
• Atrial fibrillation or other arrhythmias.
• Severe hypotension leading to syncope.
• Persistent visual loss or retinal abnormalities.
• Hepatic enzyme elevation indicating possible liver injury.

Before initiating Ivabradina Sandoz, clinicians should consider several safety measures.

• Baseline heart rate: ensure resting rate is ≥60 bpm before starting therapy.
• Concomitant bradycardic agents: evaluate need for dose adjustment or monitoring.
• Severe hepatic impairment: use with caution or avoid.
• Pregnancy and lactation: assess risk‑benefit, as safety data are limited.
• Elderly patients: monitor for increased sensitivity to heart‑rate effects.
• Store below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Ivabradina Sandoz may interact with other medicines; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase ivabradine exposure.
• Co‑administration with other heart‑rate‑lowering drugs (beta‑blockers, digoxin, diltiazem): risk of excessive bradycardia.
• Concomitant use with drugs that cause QT prolongation: may increase arrhythmic risk.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce ivabradine effectiveness.

• Verapamil or diltiazem (moderate CYP3A4 inhibitors): may require dose adjustment.
• Alcohol consumption: can enhance bradycardic effects and should be limited.